The Use of Genetics in Guiding Therapy

CYP2C19 and Response to Clopidogrel

June 2012

As mentioned in the previous slide, clopidogrel is given as a prodrug. It is metabolized to its active form by CYP2C19 and other enzymes. CYP2C19 has several loss of function alleles, but the two alleles that have been studied the most in relation to clopidogrel are the *2 and *3 alleles, for which you can see their ethnic distribution here. These alleles are associated with lower levels of active metabolite of clopidogrel and a marked decrease in platelet responsiveness to clopidogrel (in other words, higher on-treatment platelet aggregation).

< Previous Slide

CYP2C19 and Response to Clopidogrel

Next Slide >

 

Jump to section:

• Introduction
• Pharmacogenomics
• PGx Biomarkers in Drug Labels
• FDA-Approved Drugs with PGx-Related Label Information
• FDA-Approved Drugs with PGx-Related Label Information
• The FDA and PGx-Related Drug Label Updates
• Clopidogrel (Plavix)
• CYP2C19 and Response to Clopidogrel
• CYP2C19 and Response to Clopidogrel (cont)
• CYP2C19 PGx Testing for Clopidogrel
• Mayo CYP2C19 Test
• The FDA and PGx-Related Drug Label Updates
• Warfarin
• Warfarin PGx
• Allele Frequencies
• Medco-Mayo Warfarin Effectiveness Study
• Mayo Test for Warfarin Sensitivity
• FDA-Approved Drugs with PGx-Related Label Information
• Most Psychotropic Medications Are Metabolized by CYPs
• CYP450 Testing — Psychotherapeutics
• CYP2D6
• Mayo Test for CYP2D6
• Mayo Tests for CYP2D6
• Additional Mayo Tests for Psychiatric Applications
• The FDA and PGx-Related Drug Label Updates
• UGT1A1
• Irinotecan Metabolism
• UGT1A1 Genetic Variants
• Mayo Tests for UGT1A1
• The FDA and PGx-Related Drug Label Updates
• Human Leukocyte Antigens and Drug Hypersensitivity
• HLA-B*1502
• Mayo Test for HLA-B*1502
• HLA-B*5701
• Mayo Test for HLA-B*5701
• Summary
• Questions